This study is conducted in Europe. The aim of the study is to update the knowledge about the prevalence and severity of congenital haemophilia (A and B) in Spain.
Study Type
OBSERVATIONAL
Enrollment
1,157
Patients will not be treated with any specific product. Data collection only.
Unnamed facility
Madrid, Spain
Prevalence of congenital haemophilia A and B in Spain in 2013, described as proportion (%) of patients in the total population (extracted from the last available census of the Spanish population for the regions considered for the study)
Time frame: Assessed at study visit (day 1)
Severity (mild, moderate or severe) of congenital haemophilia A and B in Spain during 2013, described as proportion (%) per category of the total number of patients with haemophilia A or B
Time frame: Assessed at study visit (day 1)
Mean current age at the time of visit to the HTC in 2013
Time frame: Assessed at study visit (day 1)
Mean age at diagnosis
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients with/without genetic screening performed
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients who needed support of a reference Haemophilia Healthcare Centre in 2013
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients who received plasmatic or recombinant treatment
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients who received on demand or prophylaxis treatment
Time frame: Assessed at study visit (day 1)
Mean number of bleeding episodes
Time frame: Assessed at study visit (day 1)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mean number of joint bleeds
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients with established arthropathy
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients with infectious complications
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients with HIV (Human immunodeficiency virus)
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients with presence of inhibitors
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients with immune tolerance induction treatment performed
Time frame: Assessed at study visit (day 1)
Total number of surgery interventions performed
Time frame: ThAssessed at study visit (day 1)
Proportion (%) of patients with quality of life questionnaire (QoLQ) performed in 2013
Time frame: Assessed at study visit (day 1)
Mean number of days of absenteeism to school/university in children and adolescents in 2013
Time frame: Assessed at study visit (day 1)
Mean number of days of absenteeism from work in 2013
Time frame: Assessed at study visit (day 1)
Proportion (%) of patients with treatment administered at home
Time frame: Assessed at study visit (day 1)